These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 12427118)

  • 21. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
    Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
    Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
    Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
    Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme Replacement Therapy Clears Gb3 Deposits from a Podocyte Cell Culture Model of Fabry Disease but Fails to Restore Altered Cellular Signaling.
    Braun F; Blomberg L; Brodesser S; Liebau MC; Schermer B; Benzing T; Kurschat CE
    Cell Physiol Biochem; 2019; 52(5):1139-1150. PubMed ID: 30990584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
    PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
    Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
    J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.
    Shin YJ; Jeon YJ; Jung N; Park JW; Park HY; Jung SC
    Mol Med Rep; 2015 Oct; 12(4):5049-57. PubMed ID: 26135632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
    Eto Y; Ohashi T; Utsunomiya Y; Fujiwara M; Mizuno A; Inui K; Sakai N; Kitagawa T; Suzuki Y; Mochizuki S; Kawakami M; Hosoya T; Owada M; Sakuraba H; Saito H
    J Inherit Metab Dis; 2005; 28(4):575-83. PubMed ID: 15902561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.
    Vedder AC; Breunig F; Donker-Koopman WE; Mills K; Young E; Winchester B; Ten Berge IJ; Groener JE; Aerts JM; Wanner C; Hollak CE
    Mol Genet Metab; 2008 Jul; 94(3):319-25. PubMed ID: 18424138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy for Fabry disease, an inherited nephropathy.
    Desnick RJ; Banikazemi M; Wasserstein M
    Clin Nephrol; 2002 Jan; 57(1):1-8. PubMed ID: 11837797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fabry nephropathy in a female with superposed IgA glomerulonephritis].
    Pisani A; Sessa A; Sabbatini M; Andreucci MV; Fusco C; Balletta M; Cianciaruso B
    G Ital Nefrol; 2005; 22(4):385-9. PubMed ID: 16267800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease.
    Lorenzen JM; Dietrich B; Fiedler J; Jazbutyte V; Fleissner F; Karpinski N; Weidemann F; Wanner C; Asan E; Caprio M; Ertl G; Bauersachs J; Thum T
    Basic Res Cardiol; 2013 Jan; 108(1):311. PubMed ID: 23184391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequelae of storage in Fabry disease--pathology and comparison with other lysosomal storage diseases.
    Elleder M
    Acta Paediatr Suppl; 2003 Dec; 92(443):46-53; discussion 45. PubMed ID: 14989466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.
    Itier JM; Ret G; Viale S; Sweet L; Bangari D; Caron A; Le-Gall F; Bénichou B; Leonard J; Deleuze JF; Orsini C
    J Inherit Metab Dis; 2014 Nov; 37(6):1013-22. PubMed ID: 24850378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria.
    Tøndel C; Kanai T; Larsen KK; Ito S; Politei JM; Warnock DG; Svarstad E
    Nephron; 2015; 129(1):16-21. PubMed ID: 25531941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects.
    Giugliani R; Waldek S; Germain DP; Nicholls K; Bichet DG; Simosky JK; Bragat AC; Castelli JP; Benjamin ER; Boudes PF
    Mol Genet Metab; 2013 May; 109(1):86-92. PubMed ID: 23474038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
    Najafian B; Svarstad E; Bostad L; Gubler MC; Tøndel C; Whitley C; Mauer M
    Kidney Int; 2011 Mar; 79(6):663-670. PubMed ID: 21160462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
    Schiffmann R; Goker-Alpan O; Holida M; Giraldo P; Barisoni L; Colvin RB; Jennette CJ; Maegawa G; Boyadjiev SA; Gonzalez D; Nicholls K; Tuffaha A; Atta MG; Rup B; Charney MR; Paz A; Szlaifer M; Alon S; Brill-Almon E; Chertkoff R; Hughes D
    J Inherit Metab Dis; 2019 May; 42(3):534-544. PubMed ID: 30834538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
    Mauer M; Sokolovskiy A; Barth JA; Castelli JP; Williams HN; Benjamin ER; Najafian B
    J Med Genet; 2017 Nov; 54(11):781-786. PubMed ID: 28756410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.